EA THORACIC COMMITTEE CO-CHAIR HEATHER WAKELEE, MD BECOMES PRESIDENT-ELECT OF INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)

Dr. Heather Wakelee, Professor of Medicine in the Division of Oncology at Stanford University and faculty director of the Stanford Cancer Clinical Trials Office, was recently elected to become the President-Elect of IASLC, the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. After two years in this role with active work on the Executive Committee, she will become President in 2021. She previously served on the IASLC Board of Directors, as Chair of the Communications Committee, as a USA Regent and as Co-Chair of the NACLC (formerly Chicago Multidisciplinary Symposium in Thoracic Oncology).

Dr. Wakelee is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her post-graduate training at Stanford University. She has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies, including thymic malignancies, and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics in addition to collaborative efforts in population sciences. Dr. Wakelee is passionate about mentorship and is dedicated to multidisciplinary care. She is delighted to work with an amazing team of nurses, advanced practice providers, clinical research coordinators and physician colleagues.

Dr. Wakelee has been an active ECOG-ACRIN investigator for her entire academic career. Many of her early publications were secondary analyses of EA trials. She was the study chair of E1505, a phase III trial involving 1500 patients who received adjuvant therapy after resection of early stage non-small cell lung cancer. Though the trial was negative, important biomarker analyses are ongoing. She is currently the Thoracic Committee Co-Chair and a member of the EA Executive Committee. In 2015 she was awarded the EA Young Investigator Award. Dr. Wakelee is also active in the American Society of Clinical Oncology (ASCO) and received the Fellow of ASCO (FASCO) award in 2019.